Long Hot Summer For Novel Drug Reviews Forecast At US FDA
Executive Summary
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
You may also be interested in...
Generic Drug Approvals Still Winning The Pandemic At US FDA
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.
Generic Drug Approvals Still Winning The Pandemic At US FDA
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.
The End Of The FDA Approvals Boom? Fewer Applications Are A COVID-19 Consequence
Applications for US FDA approval are lower than in recent history, portending a lean 2021.